AR087276A1 - COMPOSITIONS AND METHODS TO TREAT VERA POLICITEMY AND ESSENTIAL THROMBOCITEMIA - Google Patents

COMPOSITIONS AND METHODS TO TREAT VERA POLICITEMY AND ESSENTIAL THROMBOCITEMIA

Info

Publication number
AR087276A1
AR087276A1 ARP120102656A ARP120102656A AR087276A1 AR 087276 A1 AR087276 A1 AR 087276A1 AR P120102656 A ARP120102656 A AR P120102656A AR P120102656 A ARP120102656 A AR P120102656A AR 087276 A1 AR087276 A1 AR 087276A1
Authority
AR
Argentina
Prior art keywords
methods
compositions
vera
essential
thrombocitemia
Prior art date
Application number
ARP120102656A
Other languages
Spanish (es)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR087276A1 publication Critical patent/AR087276A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

Composiciones y métodos para tratar policitemia vera (PV) y/o trombocitemia esencial (ET) en un sujeto. Los métodos comprenden administrar al sujeto una cantidad eficaz de compuesto que es N-terc-butil-3-[(5-metil-2-{[4-(2-pirrolidin-1-iletoxi)fenil]amino}pirimidin-4-il)amino]bencenosulfonamida o una sal farmacéuticamente aceptable o un hidrato de éste.Compositions and methods for treating polycythemia vera (PV) and / or essential thrombocythemia (ET) in a subject. The methods comprise administering to the subject an effective amount of compound which is N-tert-butyl-3 - [(5-methyl-2 - {[4- (2-pyrrolidin-1-ylethoxy) phenyl] amino} pyrimidin-4- il) amino] benzenesulfonamide or a pharmaceutically acceptable salt or a hydrate thereof.

ARP120102656A 2011-07-21 2012-07-20 COMPOSITIONS AND METHODS TO TREAT VERA POLICITEMY AND ESSENTIAL THROMBOCITEMIA AR087276A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161510409P 2011-07-21 2011-07-21
US201161510406P 2011-07-21 2011-07-21
FR1251748 2012-02-27
FR1251749 2012-02-27

Publications (1)

Publication Number Publication Date
AR087276A1 true AR087276A1 (en) 2014-03-12

Family

ID=47558514

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102656A AR087276A1 (en) 2011-07-21 2012-07-20 COMPOSITIONS AND METHODS TO TREAT VERA POLICITEMY AND ESSENTIAL THROMBOCITEMIA

Country Status (3)

Country Link
AR (1) AR087276A1 (en)
TW (1) TW201316989A (en)
WO (1) WO2013013195A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
FR3092581A1 (en) * 2019-02-12 2020-08-14 Impact Biomedicines, Inc CRYSTALLINE FORMS OF A JAK2 INHIBITOR
WO2020167845A1 (en) * 2019-02-12 2020-08-20 Impact Biomedicines, Inc. Crystalline forms of a jak2 inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025685A1 (en) * 2009-08-24 2011-03-03 Merck Sharp & Dohme Corp. Jak inhibition blocks rna interference associated toxicities

Also Published As

Publication number Publication date
TW201316989A (en) 2013-05-01
WO2013013195A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
ECSP13012658A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HONEYFIBROSIS
BR112014016805A2 (en) therapeutically active compounds and their methods of use
EA201490194A1 (en) COMBINED THERAPY, INCLUDING CDK4 / 6 INHIBITOR AND PI3K INHIBITOR FOR USE IN CANCER TREATMENT
CL2016000241A1 (en) Formulation of syk inhibitors.
GT201400009A (en) 4-IMIDAZOPIRIDAZIN-1-IL-BENZAMIDAS AND 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDAS AS BTK INHIBITORS
EA201201680A1 (en) MORFOLINOPYRIMIDINES AND THEIR APPLICATION IN THERAPY
GT201300266A (en) PIRROLOTRIAZINONA DERIVATIVES AS PI3K INHIBITORS
BR112013025386A2 (en) combination of a compound, compound of formula ia or a pharmaceutically acceptable salt thereof, method for treating a braf v600e mutation-modulated disease or disorder and high levels of pakt in a mammal and use
MX2021008610A (en) Cancer treatment using combinations of erk and raf inhibitors.
CL2013001093A1 (en) Tricyclic compounds that inhibit the kinase pi3 (pi3k); pharmaceutical composition that includes them; method to treat cancer; and its use for the treatment of cancer.
EA201391285A1 (en) Derivatives of tetrahydroquinoline, useful as bromodomain inhibitors
IN2014MN01755A (en)
IN2014DN10386A (en)
EA201500265A1 (en) ANTI-FLY VIRUS REPLICATION INHIBITORS
BR112014007622A2 (en) macrocyclic flt3 kinase inhibitors
ECSP13012764A (en) IMIDAZO COMPOUND [4,5-C] QUINOLIN-2-ONA AND ITS USE AS A DUAL INHIBITOR OF KINASE PI3 / mTOR
ECSP13013011A (en) TRIAZOLOPIRIDINS
MX2014003025A (en) Triazolopyridine compounds as pde10a inhibitors.
DOP2013000131A (en) COMPOSITIONS AND METHODS TO TREAT CANCER USING A PI3K INHIBITOR AND A MEK INHIBITOR
BR112013017953A2 (en) PHARMACEUTICAL COMPOSITION, TOPICAL FORMULATION, METHOD, AND PHOTOSENSITIZING COMPOSITION
AR087276A1 (en) COMPOSITIONS AND METHODS TO TREAT VERA POLICITEMY AND ESSENTIAL THROMBOCITEMIA
BR112012027813A2 (en) piperazinotriazines as pi3k inhibitors for use in the treatment of antiproliferative disorders
MX2013014398A (en) Heterocyclic sulfonamide derivatives.
CL2013003556A1 (en) Phthalazinone-pyrrolo [3,2-d] pyrimidine-carboxamide derivatives, phosphodiesterase type 4 and type 5 inhibitors; pharmaceutical composition that comprises or fixed combination, not fixed and kit, use of the compound in the preparation of a medicament for treating respiratory tract diseases
BR112015005392A2 (en) tablet formulation of a phosphatidylinositol 3 kinase inhibitor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal